NCT00223067Unknown1 期
A Multi-Center Open-Labeled Study of the Administration of Allogenic and Autologous Regulatory Cells for the Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor)
University Hospital Schleswig-Holstein2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2005年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- graft survival and reduction or withdrawal of immunosuppressives after treatment with Transplant-Acceptance Inducing Cells (TAIC) and autologous regulatory T cells (tregs)
研究概览
简要总结
reduce of immunsupression or introduce tolerance with so called TAIZ-monocytes in renal transplant patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all the following inclusion criteria to be considered for admission to the trial:
- •Male or female adult patients aged between 18 and 64 years (inclusive). A female of childbearing potential may be enrolled provided she:
- •has a negative pregnancy test at Screening and
- •is routinely using adequate contraception prior to and during the study and
- •agrees not to attempt to become pregnant during the study and
- •is not lactating A female of non-childbearing potential will be defined as one who has been postmenopausal for at least one year or has been surgically sterilised.
- •Patients receiving a first renal transplant.
- •Patients who fulfil the criteria to receive an allogenic renal transplant (according to the Eurotransplant (ET) manual on organ allocation and the Bundesärztekammer allocation criteria) and who are listed on a waiting list.
- •Patients who, after the nature of the study and the disclosure of their data has been explained to them, have freely given Informed Consent in writing.
- •In vitro demonstration of the suppressive effect of the donor TAIC for the donor-recipient pair.
排除标准
- •(for the recipient)
- •Exclusion Criteria (for the recipient):
- •Patients presenting any of the following exclusion criteria must not be included in the trial:
- •Patients who have received a renal transplant.
- •Patients who have an active infection at the time of entry into the study (Screening).
- •Recipient and donor pairs who show the following incompatible EBV or CMV constellation: the donor is EBV or CMV positive and the recipient is EBV or CMV negative.
- •Patients and/or donors who have positive evidence of HIV or have active virus hepatitis B and C.
- •Patients with a history of alcohol and/or drug abuse or sepsis.
- •Patients who are pregnant women or nursing mothers.
- •Known hypersensitivity or contraindication to one of the immunosuppressives administered during the course of the study: ATG, tacrolimus, or steroids (prednisolone).
- •Patients with a history or present symptoms of autoimmune vasculitis.
- •Detection of > 5% HLA antibodies (all current and historic values).
- •Patients with a malignancy or history of malignancy.
- •Patients with renal insufficiency due to a vasculitis.
- •Patients whose condition requires continuous systemic administration of immunosuppressives.
- •Missing immunosuppressive effect of the donor TAIC for the donor-recipient pair in vitro test.
- •Patients who are simultaneously participating or plan to participate in any other clinical study.
- •Psychiatric or emotional problems or lack of knowledge of the German language which would invalidate the giving of Informed Consent or limit the ability of the subject to comply with study requirements.
- •Unwillingness or inability to provide Informed Consent or to participate satisfactorily for the entire trial period
- •Patients with corresponding donors presenting any one of the exclusion criteria documented in the Eurotransplant guidelines ( ) must not be included in the trial.
结局指标
主要结局
graft survival and reduction or withdrawal of immunosuppressives after treatment with Transplant-Acceptance Inducing Cells (TAIC) and autologous regulatory T cells (tregs)
serum creatinine
rejection episodes
necessity for re-introduction of any immunosuppressives.
次要结局
- safety and tolerability of the treatment with Transplant-Acceptance Inducing Cells (TAIC) in terms of rejection episodes and Adverse Events (AEs)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)Renal TransplantationNCT00223093University Hospital Schleswig-Holstein10
已完成
4 期
HARMONY:A triple arm, prospectively randomized, multi-center study phase IV to evaluate calcineurin inhibitor reduced and steroid-free immunosupression in low immunological risk patients.Z94.0Kidney transplant statusDRKS00000452niversitätsklinikum Freiburg631
Unknown
不适用
Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf TestKidney Transplant RejectionImmunosuppressionNCT04670926Transplant Genomics, Inc.75
已完成
4 期
Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal TransplantationDisorder Related to Renal TransplantationNCT00724022University Hospital Freiburg600
Unknown
4 期
CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant RecipientsRenal TransplantNCT00737659Rabin Medical Center138